Genprex Inc
NASDAQ:GNPX

Watchlist Manager
Genprex Inc Logo
Genprex Inc
NASDAQ:GNPX
Watchlist
Price: 1.8 USD 0.56% Market Closed
Market Cap: 4.1m USD

Genprex Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Genprex Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Genprex Inc
NASDAQ:GNPX
Operating Income
-$21.2m
CAGR 3-Years
-1%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Genprex Inc
Glance View

Market Cap
4.1m USD
Industry
Biotechnology

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 17 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing treatments for cancer and diabetes. The firm's lead cancer drug candidate, REQORSA Immunogen therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a multifunctional gene that helps in cancer suppression and normal cell regulation. The firm utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

GNPX Intrinsic Value
0.49 USD
Overvaluation 73%
Intrinsic Value
Price

See Also

What is Genprex Inc's Operating Income?
Operating Income
-21.2m USD

Based on the financial report for Dec 31, 2024, Genprex Inc's Operating Income amounts to -21.2m USD.

What is Genprex Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-15%

Over the last year, the Operating Income growth was 32%. The average annual Operating Income growth rates for Genprex Inc have been -1% over the past three years , -15% over the past five years .

Back to Top